Skip to main content

A new type of COVID-19 test now approved for use could help with frontline diagnostics

The U.S. Food and Drug Administration (FDA) is moving much more quickly to grant special ’emergency use authorization’ to equipment and tests that could help increase testing for the novel coronavirus in the U.S., which lags behind most countries in the world when it comes to tests conducted relative to the size of its population. One type of test just approved for use could help expand the availability of frontline testing in hospitals and at clinics where patients are receiving care – without requiring round-tripping to a dedicated diagnostics lab.

Cepheid’s COVID-19 test, which the agency approved this week, also has the advantage of being able to be run either with or without use of a nasal swab, which is key because supplies of nasal swabs are taxed globally in light of the need for testing. It’s also a molecular, PCR-based test, with high rates of accuracy just like the lab-based testing that’s already in place across facilities in the U.S., but it uses the company’s GeneXpert machine (basically a diagnostics kit the size of an inkjet printer cartdrige lab in a box roughly the size of an inkjet printer) to produce results on-site.

Cepheid says that around 23,000 of its GeneXpert micro-labs are already in use around the world, with around 5,000 of those located in the U.S. The company’s hardware has been running tests for the flu for years already, with high reliability rates. The new COVID-19 tests for the system will begin to be shipped out by the Sunnyvale-based molecular diagnostics company starting next week.

Testing in the U.S. has increased over the past week, thanks in large part to widespread efforts to expand availability especially in hard-hit regions like New York State. But the need for more tests is still pressing, as the limits of availability mean that essentially only the most severe cases, often requiring confirmed contact tracing or proof of elevated risk, are being tested. Solutions like Cepheid’s, as well as other potential alternative test methods than can be done entirely at home, like Scanwell’s forthcoming test that looks for antibodies in a person’s blood, are much-needed if we hope to truly expand testing to a degree that it can properly inform any coronavirus mitigation strategy.



from TechCrunch https://ift.tt/399EaSl
Labels:

Comments

Post a Comment

Popular posts from this blog

Apple rolls out Apple Card Preview to select users

Apple Card is getting its first group of public test users today. A limited amount of customers that signed up to be notified about the release of Apple Card are getting the ability to apply for the card in their Wallet app today — as well as the option to order their physical Apple Card. I’ve been using the card for a few days on my own device, making purchases and payments and playing around with features like Apple Cash rewards and transaction categorization. A full rollout of Apple Card will come later in August. It requires iOS 12.4 and up to operate. The application process was simple for me. Portions of the information you need are pre-filled from your existing AppleID account, making for less manual entry. I had an answer in under a minute and was ready to make my first purchase instantly. I used it both online and in person with contactless terminals. It…works. The card on the screen has a clever mechanism that gives you a sort of live heat map of your spending categorie...
1 comment
Read more

HPE is buying Cray for $1.3 billion

HPE announced it was buying Cray for $1.3 billion, giving it access to the company’s high performance computing portfolio, and perhaps a foothold into quantum computing in the future. The purchase price was $35 a share, a $5.19 premium over yesterday’s close of $29.81 a share. Cray was founded in the 1970s and for a time represented the cutting edge of super computing in the United States, but times have changed, and as the market has shifted, a deal like this makes sense. Ray Wang, founder and principal analyst at Constellation Research says this is about consolidation at the high end of the market. “This is a smart acquisition for HPE. Cray has been losing money for some time but had a great portfolio of IP and patents that is key for the quantum era,” he told TechCrunch. While HPE’s president and CEO Antonio Neri didn’t see it in those terms, he did see an opportunity in combining the two organizations. “By combining our world-class teams and technology, we will have the oppor...
Post a Comment
Read more

A fight is brewing between two machine intelligence startups, and neither side looks all that smart

Sometimes, reading a lawsuit, it’s tempting to pick sides, to judge who is more right than wrong based on its contents. But a new lawsuit involving two venture-backed companies — both of which are rooted in machine intelligence — makes both sides sound surprisingly careless given their line of work. The plaintiff is Quid , a now 12-year-old company that has raised roughly $108 million from investors, shows Crunchbase. Its newest, $38 million round closed in October, led by REV Ventures, the investment arm of LexisNexis owner RELX Group , and it included participation from some very heavy hitters, including Tiger Global founder Julian Robertson and KKR cofounder Henry Kravis. Quid calls itself a “platform that searches, analyzes and visualizes the world’s collective intelligence to help answer strategic questions.” As company cofounder Bob Goodson has described the company , its software scours the internet, including company websites, news databases and social media postings to help...
Post a Comment
Read more